Gx™ Lynch Syndrome Gene Testing

Sequence and Dup/Del analysis of 5 genes for the diagnosis or risk assessment of Lynch Syndrome

Lynch Syndrome is the most common cause of hereditary colon cancer and increases the risk for many other cancer types including endometrial and ovarian carcinomas

Lynch syndrome is an inherited condition of a higher risk of cancers in the digestive and gynecologic tracts, and other organs.  People who have Lynch syndrome have a significantly increased risk of developing colorectal cancer, endometrial (uterine) cancer, ovarian cancer, gastric (stomach) cancer, small bowel (small intestinal) cancer, pancreatic cancer, urinary track (bladder or ureter) cancer, kidney cancer, bile duct cancer, brain cancer, and certain skin tumors (sebaceous adenomas). People with Lynch syndrome may also be at slightly increased risk of breast cancer and prostate cancer. Lynch syndrome is often called hereditary nonpolyposis colorectal cancer (HNPCC), and is the most common cause of hereditary colon cancer. 

Gx-Lynch Syndrome Gene Testing (Gx™ LynS)

Sequencing and Dup/Del analysis of 5 known Lynch Syndrome genes, EPCAM, MLH1, MSH2, MSH6, PMS2. Identification of Lynch syndrome can aid in the most effective surveillance and treatment of cancer.

Candidates for Gx-LynS Testing

  • Patient with endometrial and ovarian carcinomas
  • Patient with colorectal cancer (regardless of age)
  • Patient with personal history of abnormal screening test results of tumor tissue, including:
    • MSI testing of tumor tissue with high instability
    • IHC testing of tumor tissue with negative staining
  • Patient with at least 2 or strong family history of Lynch syndrome-related cancers
  • Patient with blood relative with Lynch syndrome

5 Genes Sampled